Cargando…

Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study

INTRODUCTION: Serious cardiac arrhythmias caused by QT-prolonging drugs are difficult to predict based on physiological measurement and pre-approval clinical trials. Post-marketing surveillance and monitoring are important to generate safety data. OBJECTIVES: To assess whether an observational study...

Descripción completa

Detalles Bibliográficos
Autores principales: Fung, Kin Wah, Baye, Fitsum, Kapusnik-Uner, Joan, McDonald, Clement J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875170/
https://www.ncbi.nlm.nih.gov/pubmed/33569737
http://dx.doi.org/10.1007/s40801-021-00230-1
_version_ 1783649733230723072
author Fung, Kin Wah
Baye, Fitsum
Kapusnik-Uner, Joan
McDonald, Clement J.
author_facet Fung, Kin Wah
Baye, Fitsum
Kapusnik-Uner, Joan
McDonald, Clement J.
author_sort Fung, Kin Wah
collection PubMed
description INTRODUCTION: Serious cardiac arrhythmias caused by QT-prolonging drugs are difficult to predict based on physiological measurement and pre-approval clinical trials. Post-marketing surveillance and monitoring are important to generate safety data. OBJECTIVES: To assess whether an observational study using Medicare claims data can detect the arrhythmogenic risk of QT-prolonging drugs. METHODS: We identified 17 QT-prolonging drugs with known risk of torsades des pointes (TdP) that were not used to treat cardiac arrhythmias. Amoxicillin and four serotonin-norepinephrine reuptake inhibitors (SNRIs) were used as controls. De-identified claims data of 1.2 million Medicare beneficiaries were accessed. Two separate Cox regressions were done for short-term and chronic-use drugs. The primary outcome was a composite of ventricular arrhythmias and/or sudden death, identified by ICD diagnostic codes. We explored the independent effect of each study drug on the outcomes. Other covariates included patient demographics, comorbidities, and known risk factors for drug-induced cardiac arrhythmia. RESULTS: We were able to detect increased risk in 14 of 17 study drugs (82.3%), and none of the control drugs. Among the fluoroquinolones, ciprofloxacin was the safest. Azithromycin and clarithromycin were relatively safe compared to erythromycin. Compared to SNRIs, both citalopram and escitalopram had increased risk, more so with escitalopram than citalopram. Comorbidities associated with increased risk included ischemic heart disease, electrolyte imbalance, bradycardia, acute myocardial infarction, heart failure, and chronic kidney and liver disease. CONCLUSION: Medicare data can be utilized for post-marketing surveillance and monitoring of the proarrhythmic risk of QT-prolonging drugs in older adults. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-021-00230-1.
format Online
Article
Text
id pubmed-7875170
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78751702021-02-11 Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study Fung, Kin Wah Baye, Fitsum Kapusnik-Uner, Joan McDonald, Clement J. Drugs Real World Outcomes Original Research Article INTRODUCTION: Serious cardiac arrhythmias caused by QT-prolonging drugs are difficult to predict based on physiological measurement and pre-approval clinical trials. Post-marketing surveillance and monitoring are important to generate safety data. OBJECTIVES: To assess whether an observational study using Medicare claims data can detect the arrhythmogenic risk of QT-prolonging drugs. METHODS: We identified 17 QT-prolonging drugs with known risk of torsades des pointes (TdP) that were not used to treat cardiac arrhythmias. Amoxicillin and four serotonin-norepinephrine reuptake inhibitors (SNRIs) were used as controls. De-identified claims data of 1.2 million Medicare beneficiaries were accessed. Two separate Cox regressions were done for short-term and chronic-use drugs. The primary outcome was a composite of ventricular arrhythmias and/or sudden death, identified by ICD diagnostic codes. We explored the independent effect of each study drug on the outcomes. Other covariates included patient demographics, comorbidities, and known risk factors for drug-induced cardiac arrhythmia. RESULTS: We were able to detect increased risk in 14 of 17 study drugs (82.3%), and none of the control drugs. Among the fluoroquinolones, ciprofloxacin was the safest. Azithromycin and clarithromycin were relatively safe compared to erythromycin. Compared to SNRIs, both citalopram and escitalopram had increased risk, more so with escitalopram than citalopram. Comorbidities associated with increased risk included ischemic heart disease, electrolyte imbalance, bradycardia, acute myocardial infarction, heart failure, and chronic kidney and liver disease. CONCLUSION: Medicare data can be utilized for post-marketing surveillance and monitoring of the proarrhythmic risk of QT-prolonging drugs in older adults. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40801-021-00230-1. Springer International Publishing 2021-02-10 /pmc/articles/PMC7875170/ /pubmed/33569737 http://dx.doi.org/10.1007/s40801-021-00230-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Fung, Kin Wah
Baye, Fitsum
Kapusnik-Uner, Joan
McDonald, Clement J.
Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title_full Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title_fullStr Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title_full_unstemmed Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title_short Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
title_sort using medicare data to assess the proarrhythmic risk of non-cardiac treatment drugs that prolong the qt interval in older adults: an observational cohort study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875170/
https://www.ncbi.nlm.nih.gov/pubmed/33569737
http://dx.doi.org/10.1007/s40801-021-00230-1
work_keys_str_mv AT fungkinwah usingmedicaredatatoassesstheproarrhythmicriskofnoncardiactreatmentdrugsthatprolongtheqtintervalinolderadultsanobservationalcohortstudy
AT bayefitsum usingmedicaredatatoassesstheproarrhythmicriskofnoncardiactreatmentdrugsthatprolongtheqtintervalinolderadultsanobservationalcohortstudy
AT kapusnikunerjoan usingmedicaredatatoassesstheproarrhythmicriskofnoncardiactreatmentdrugsthatprolongtheqtintervalinolderadultsanobservationalcohortstudy
AT mcdonaldclementj usingmedicaredatatoassesstheproarrhythmicriskofnoncardiactreatmentdrugsthatprolongtheqtintervalinolderadultsanobservationalcohortstudy